31. EILF-Italian migrants study: An HCV and HBV micro elimination pilot project. (March 2021) Authors: Colucci, G.; Uceda Renteria, S.; Lunghi, G.; Ceriotti, F.; Sguazzini, E.; Spalenza, S.; Regazzo, C.; Scotti, S.; Renesto, E.; Zucchetti, A.; Paratore, C.; Lampertico, P.; Colombo, M. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients. Issue 1 (16th February 2017) Authors: Viganò, M.; Grossi, G.; Loglio, A.; Cappelletti, M.; Zaltron, S.; Castelli, F.; Andreone, P.; Messina, V.; Ganga, R.; Coppola, N.; Marrone, A.; Russello, M.; Marzano, A.; Taliani, G.; Fasano, M.; Fagiuoli, S.; Villa, E.; Bronte, F.; Santantonio, T.; Brancaccio, G. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Issue 1 (16th February 2017) Authors: Manini, M.A.; Bruce, M.; Carey, I.; Whitehouse, G.; Wang, B.; Gonsalkorala, E.; Considine, A.; Lampertico, P.; Agarwal, K. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. Epidemiology, features and outcomes of patients transplanted for hepatocellular carcinoma in the last decade: a single center experience. (February 2020) Authors: Invernizzi, F.; Iavarone, M.; Dondossola, D.; Antonelli, B.; Zefilippo, A.; De Feo, T.; Maggioni, M.; Sangiovanni, A.; Lampertico, P.; Rossi, G.; Donato, M.F. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
35. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group. Issue 1 (February 2018) Authors: Degasperi, E.; Pasulo, L.; Aghemo, A.; Puoti, M.; Zaltron, S.; Maggiolo, F.; Rizzardini, G.; Fargion, S.; Sacchi, P.; Gulminetti, R.; Zuin, M.; Quirino, T.; Rumi, M.G.; Pan, A.; Grossi, P.; Rossini, A.; Corbellini, A.; Uberti Foppa, C.; Colli, A.; Piovesan, S. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
36. Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. Issue 1 (February 2018) Authors: Iavarone, M.; Loglio, A.; Grossi, G.; Viganò, M.; Facchetti, F.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
37. Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network. Issue 1 (February 2018) Authors: Degasperi, E.; Pasulo, L.; Aghemo, A.; Puoti, M.; Zaltron, S.; Maggiolo, F.; Rizzardini, G.; Fargion, S.; Sacchi, P.; Gulminetti, R.; Zuin, M.; Quirino, T.; Rumi, M.G.; Pan, A.; Grossi, P.; Rossini, A.; Corbellini, A.; Uberti Foppa, C.; Colli, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
38. Excellent long-term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: A case series. (March 2021) Authors: Loglio, A.; Ferenci, P.; Renteria, SC. Uceda; Holzmann, H.; Borghi, M.; Perbellini, R.; Rimondi, A.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Prati, D.; Ceriotti, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
39. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di). (March 2023) Authors: Anolli, M.P.; Degasperi, E.; D'Offizi, G.; Brunetto, M.R.; Verucchi, G.; Federico, A.; Ciancio, A.; Mangia, A.; Santantonio, T.A.; Coppola, N.; Pellicelli, A.; Loglio, A.; Viganò, M.; Pileri, F.; Maracci, Monia; Puoti, M.; Piscaglia, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
40. Factor VIII/Protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score. (February 2020) Authors: Bitto, N.; Tosetti, G.; Tripodi, A.; Mancini, I.; Baronciani, L.; Valsecchi, C.; Lampertico, P.; Peyvandi, F.; Primignani, M.; La Mura, V. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗